Related references
Note: Only part of the references are listed.WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders
Jan Jacques Michiels et al.
LEUKEMIA RESEARCH (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
Thomas Stauffer Larsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth
Zhe Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis
Costanza Bogani et al.
HAEMATOLOGICA (2007)
JAK-2 mutations and their relevance to myeloproliferative disease
Ross L. Levine et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2
Megumi Funakoshi-Tago et al.
EMBO JOURNAL (2006)
The role of Janus kinases in haemopoiesis and haematological malignancy
Asim Khwaja
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system
Ayalew Tefferi et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2006)
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
XH Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
J Jelinek et al.
BLOOD (2005)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
RL Levine et al.
BLOOD (2005)
Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case
S Heiss et al.
HUMAN PATHOLOGY (2005)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes
DP Steensma et al.
BLOOD (2005)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
A Reiter et al.
CANCER RESEARCH (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
P Saharinen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
